Prostate Cancer History Was Made Today!
A non toxic, non invasive Immunotherapy to strengthen the body’s ability to fight prostate cancer achieved its goal of being supportive of the previous trials, as required by the FDA.
Mitchell Gold, Dendreon CEO, held a conference call to announce the results of the Provenge Impact Trial.
Here are some of Dr. Gold’s words concering the results: “met it’s pre specified end points” “confirms results of previous studies” “data met criteria and specifications of Biologics License Application” “results were robust” “results were unambiguous and held up to multiple sensitivity analysis” “a clear hit on statistical significance”.
It was great news for long suffering prostate cancer patients who are one step closer to gaining access to Provenge.
It was great news for people around the world seeking better, more humane treatments to fight cancer. Dendreon has a pipeline of immunotherapies on the back burner.
Here at Care To Live we are ecstatic. However our work is very far from over. We need the FDA to allow the men access to Provenge NOW!
We are already getting emails from people begging for access. The FDA needs to heed their cries, and speed the approval process through. These men have already been waiting for 2 years while the FDA dawdled. These men don’t have the luxury of wasting more time.
Mike Kearney had written to Andrew Schorr of Patient Power, to keep him updated. Mr. Schorr did a breaking news interview with a Urologist from Vanderbilt University to find out what he thought about Dendreon’s announcement today.
At the end of the interview, Andrew said “Doctor, you sound really excited about this.” The doctor said, “Yes, not only for prostate cancer but for other cancers as well.”
Recommended listening: http://www.patientpower.info/Audio/ht/HT041409.mp3a
Untold thanks to all the DENDREON team in Seattle, Washington and Hanover, New Jersey for their hard work and unending dedication, and to all the Care To Live members and supporters along with Attorney Kerry Donahue for making this day possible.
Special thanks to our devoted webmaster Matt Jurmann of ChromaticSites.com
We urge the FDA to move swiftly.